INST 0817: Compassionate Use of Mifepristone
18 Years
N/A
Both
Cancer
Trial Information
INST 0817: Compassionate Use of Mifepristone
This is a compassionate use of mifepristone treatment for patients with conditions that
could respond to an antiprogesterone agent, including:
- Meningioma.
- Breast cancer
- Colon Cancer
- Endometrial Stromal Sarcoma
- Bilateral Chronic Central Serous Retinopathy
- Cushing's Syndrome
- Metastatic Adrenocortical Cancer
- Ovarian Cancer
- Other conditions as determined by the attending physicians
Inclusion Criteria:
- All patients 18 years of age or older.
- Patients must sign an informed consent.
- Patients should be in such a health condition in the opinion of the attending
physician that with the administration of mifepristone benefits may outweigh risks.
Exclusion Criteria:
- Pregnant women or nursing mothers are not eligible for this trial. Patients of child
bearing potential must use adequate contraception.
Type of Study:
Interventional
Study Design:
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention
Outcome Measure:
Time to progression
Outcome Time Frame:
5 months or longer
Safety Issue:
No
Principal Investigator
Fa-Chyi Lee, M.D.
Investigator Role:
Principal Investigator
Investigator Affiliation:
University of New Mexico Cancer Center
Authority:
United States: Food and Drug Administration
Study ID:
INST 0817
NCT ID:
NCT00832871
Start Date:
November 2008
Completion Date:
December 2014
Related Keywords:
- Cancer
- Mifepristone
- RU-486
- Compassionate Use
- Antiprogesterone
Name | Location |
|---|---|
| Universtiy of New Mexico - Cancer Center | Albuquerque, New Mexico 87106 |
